Effect of non-statin lipid lowering and anti-obesity drugs on ldl subfractions in patients with mixed dyslipidaemia

Current Vascular Pharmacology

Volumn 8, Issue 6, 2010, Pages 820-830

  Florentin, Matilda ^a   Tselepis, Alexadros D ^b   Elisaf, Moses S ^c   Rizos, Christos V ^c   Mikhailidis, Dimitri P ^a   Liberopoulos, Evangelos N ^c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Dense LDL; Ezetimibe; Fibrates; Mixed dyslipidaemia; Nicotinic acid; Obesity; Orlistat; Rimonabant; Small

Indexed keywords

ANTILIPEMIC AGENT; ANTIOBESITY AGENT; ATORVASTATIN; BEZAFIBRATE; CIPROFIBRATE; COLESEVELAM; COLESTIPOL; EZETIMIBE; FENOFIBRATE; FISH OIL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; RIMONABANT; SIBUTRAMINE; SIMVASTATIN; TETRAHYDROLIPSTATIN;

ARTICLE; CARDIOVASCULAR RISK; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; MEDLINE; MIXED DYSLIPIDEMIA; MONOTHERAPY; OBESITY; PARTICLE SIZE; PHENOTYPE;

EID: 77956745760     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110793563825     Document Type: Article

References (86)

1. Krauss RM, Burke DJ. Identification of multiple subclasses ofplasma low density lipoproteins in normal humans. J Lipid Res1982; 23: 97-104.
2. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoproteinB metabolism. Arterioscler Thromb Vasc Biol 1997; 17: 3542-56.
3. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascularrisk assessment. QJM 2006; 99: 1-14.
4. St-Pierre AC, Ruel IL, Cantin B, et al. Comparison of variouselectrophoretic characteristics of LDL particles and their relationshipto the risk of ischemic heart disease. Circulation 2001; 104:2295-9.
5. St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoproteinsubfractions and the long-term risk of ischemic heart disease inmen: 13-year follow-up data from the Quebec CardiovascularStudy. Arterioscler Thromb Vasc Biol 2005; 25: 553-9.
6. La Belle M, Krauss RM. Differences in carbohydrate content oflow density lipoproteins associated with low density lipoproteinsubclass patterns. J Lipid Res 1990; 31: 1577-88.
7. Berneis KK, Krauss RM. Metabolic origins and clinical significanceof LDL heterogeneity. J Lipid Res 2002; 43: 1363-79.
8. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidativesusceptibility among six low density lipoprotein subfractionsof differing density and particle size. Atherosclerosis 1992; 93:189-99.
9. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small denselow-density lipoprotein particles. Expert Opin Biol Ther 2007; 7:53-72.
10. Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotypeand the risk of coronary heart disease: epidemiology, pathophysiologyand therapeutic aspects. Diabetes Metab 1999; 25: 199-211.
11. Sacks FM, Campos H. Clinical review 163: cardiovascular endocrinology:Low-density lipoprotein size and cardiovascular disease:a reappraisal. J Clin Endocrinol Metab 2003; 88: 4525-32.
12. Lada AT, Rudel LL. Associations of low density lipoprotein particlecomposition with atherogenicity. Curr Opin Lipidol 2004; 15:19-24.
13. Cromwell WC, Otvos JD. Low-density lipoprotein particle numberand risk for cardiovascular disease. Curr Atheroscler Rep 2004; 6:381-7.
14. El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of lowdensitylipoprotein particle number and size as predictors of coronaryartery disease in apparently healthy men and women: theEPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007; 49: 547-53.
15. Expert Panel on Detection, Evaluation, and Treatment of HighBlood Cholesterol in Adults. Executive Summary of the Third Reportof the National Cholesterol Education Program (NCEP).JAMA 2001; 285: 2486-97.
16. National Cholesterol Education Program (NCEP) Expert Panel onDetection, Evaluation, and Treatment of High Blood Cholesterol inAdults (Adult Treatment Panel III), final report. Third Report of theNational Cholesterol Education Program (NCEP). Circulation 2002; 106: 3143-421.
17. Gardner CD, Fortmann SP, Krauss RM. Association of small lowdensitylipoprotein particles with the incidence of coronary arterydisease in men and women. JAMA 1996; 276: 875-81.
18. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in theMonitored Atherosclerosis Regression Study (MARS). Treatmenteffects and relation to coronary angiographic progression. ArteriosclerThromb Vasc Biol 1996; 16: 697-704.
19. Gaw A, Packard CJ, Murray EF, et al. Effects of simvastatin onapoB metabolism and LDL subfraction distribution. ArteriosclerThromb 1993; 13: 170-89.
20. Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG. Effects ofatorvastatin vs. fenofibrate on lipoprotein profiles, low-densitylipoprotein subfraction distribution, and hemorheologic parametersin type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am JCardiol 2001; 87: 44-8.
21. Geiss HC, Otto C, Schwandt P, Parhofer KG. Effect of atorvastatinon low-density lipoprotein subtypes in patients with different formsof hyperlipoproteinemia and control subjects. Metabolism 2001;50: 983-8.
22. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect oforlistat and fenofibrate, alone or in combination, on small denseLDL and lipoprotein-associated phospholipase A2 in obese patientswith metabolic syndrome. Atherosclerosis 2007; 193: 428-37.
23. Nakou ES, Filippatos TD, Georgoula M, et al. The effect of orlistatand ezetimibe, alone or in combination, on serum LDL and smalldense LDL cholesterol levels in overweight and obese patients withhypercholesterolaemia. Curr Med Res Opin 2008; 24: 1919-29.
24. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesitywith specific focus on cardiovascular disease: a statement for professionalsfrom the American Heart Association Council on Nutrition,Physical Activity, and Metabolism: endorsed by the AmericanCollege of Cardiology Foundation. Circulation 2004; 110: 2952-67.
25. Bray GA. Medical consequences of obesity. J Clin EndocrinolMetab 2004; 89: 2583-9.
26. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipidsand lipoproteins of adults, 1960-2002. JAMA 2005; 294: 1773-81.
27. Tribble DL, Farnier M, Macdonell G, et al. Effects of fenofibrateand ezetimibe, both as monotherapy and in coadministration, oncholesterol mass within lipoprotein subfractions and low-densitylipoprotein peak particle size in patients with mixed hyperlipidemia.Metabolism 2008; 57: 796-801.
28. Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibemonotherapy on the concentration of lipoprotein subfractions in patientswith primary dyslipidaemia. Curr Med Res Opin 2007; 23:1169-76.
29. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, CatapanoAL. Meta-analysis of the cholesterol-lowering effect ofezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009-26.
30. Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterolassociatedactions of ezetimibe: an overview. Expert Opin TherTargets 2006; 10: 851-66.
31. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect ofezetimibe in patients who cannot tolerate statins or cannot get tothe low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007; 23: 2183-92.
32. Migdalis I, Efthimiadis A, Pappas S, Alexopoulos D, Vlasserou F, Mikhailidis DP. Clinical experience with ezetimibe/simvastatin in aMediterranean population. Curr Med Res Opin 2009; 25: 2571-6.
33. Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T. Effects of ezetimibe/simvastatin on lipoprotein subfractionsin patients with primary hypercholesterolemia: an exploratoryanalysis of archived samples using two commercially availabletechniques. Clin Ther 2007; 29: 2419-32.
34. Geiss HC, Otto C, Parhofer KG. Effect of ezetimibe on low-densitylipoprotein subtype distribution: results of a placebo-controlled,double-blind trial in patients treated by regular low-density lipoproteinapheresis and statins. Metabolism 2006; 55: 599-604.
35. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in thepathogenesis of congestive heart failure? J Am Coll Cardiol 2003;41: 105-12.
36. Rizzo M, Berneis K. The clinical significance of the size of lowdensity-lipoproteins and the modulation of subclasses by fibrates. Curr Med Res Opin 2007; 23: 1103-11.
37. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrateand their combination on metabolic parameters in overweight andobese patients with the metabolic syndrome: the FenOrli study.Curr Med Res Opin 2005; 21: 1997-2006.
38. Davidson MH, Bays HE, Stein E, Maki KC, Shalwitz RA, Doyle R. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemicsubjects. Clin Cardiol 2006; 29: 268-73.
39. Vakkilainen J, Steiner G, Ansquer JC, Perttunen-Nio H, Taskinen MR. Fenofibrate lowers plasma triglycerides and increases LDLparticle diameter in subjects with type 2 diabetes. Diabetes Care 2002; 25: 627-8.
40. Lemieux I, Salomon H, Despres JP. Contribution of apo CIII reductionto the greater effect of 12-week micronized fenofibratethan atorvastatin therapy on triglyceride levels and LDL size indyslipidemic patients. Ann Med 2003; 35: 442-8.
41. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoproteinmetabolism. Circulation 1998; 98: 2088-93.
42. Millar JS, Packard CJ. Heterogeneity of apolipoprotein B-100-containing lipoproteins: what we have learnt from kinetic studies.Curr Opin Lipidol 1998; 9: 197-202.
43. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibratereduces plasma cholesteryl ester transfer from HDL toVLDL and normalizes the atherogenic, dense LDL profile in combinedhyperlipidemia. Arterioscler Thromb Vasc Biol 1996; 16:763-72.
44. Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, MochizukiS. Fenofibrate effectively reduces remnants, and small denseLDL, and increases HDL particle number in hypertriglyceridemicmen a nuclear magnetic resonance study. J Atheroscler Thromb 2004; 11: 278-85.
45. Melenovsky V, Malik J, Wichterle D, et al. Comparison of theeffects of atorvastatin or fenofibrate on non-lipid biochemical riskfactors and the LDL particle size in subjects with combined hyperlipidemia.Am Heart J 2002; 144: E6.
46. Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate(200 mg/day) to simvastatin (10 mg/day) in patients with combinedhyperlipidemia and metabolic syndrome. Am J Cardiol 2003; 91:956-60.
47. Winkler K, Weltzien P, Friedrich I, et al. Qualitative effect offenofibrate and quantitative effect of atorvastatin on LDL profile incombined hyperlipidemia with dense LDL. Exp Clin EndocrinolDiabetes 2004; 112: 241-7.
48. Feher MD, Caslake M, Foxton J, Cox A, Packard CJ. Atherogeniclipoprotein phenotype in type 2 diabetes: reversal with micronisedfenofibrate. Diabetes Metab Res Rev 1999; 15: 395-9.
49. Tan CE, Chew LS, Tai ES, et al. Benefits of micronised Fenofibratein type 2 diabetes mellitus subjects with good glycemic control.Atherosclerosis 2001; 154: 469-74.
50. Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships betweenlow-density lipoprotein particle size, plasma lipoproteins, and progressionof coronary artery disease: the Diabetes AtherosclerosisIntervention Study (DAIS). Circulation 2003; 107: 1733-7.
51. Badiou S, Merle De Boever C, Dupuy AM, Baillat V, Cristol JP, Reynes J. Fenofibrate improves the atherogenic lipid profile andenhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004; 172: 273-9.
52. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Comparative effects of cerivastatin and fenofibrate on theatherogenic lipoprotein phenotype in proteinuric renal disease. JAm Soc Nephrol 2001; 12: 341-8.
53. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoproteinand high-density lipoprotein particle subclasses predict coronaryevents and are favorably changed by gemfibrozil therapy in theVeterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006; 113: 1556-63.
54. Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects onserum lipoprotein lipids, apolipoproteins and low density lipoproteinparticle size and relationships of lipoprotein variables to progressionof coronary artery disease in the Bezafibrate CoronaryAtherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998; 32: 1648-56.
55. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibratetherapy on cardiovascular events in 9795 people with type 2 diabetesmellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-61.
56. Secondary prevention by raising HDL cholesterol and reducingtriglycerides in patients with coronary artery disease: the BezafibrateInfarction Prevention (BIP) study. Circulation 2000; 102: 21-7.
57. Rizos E, Mikhailidis DP. Are high-density lipoprotein and triglyceridelevels important in secondary prevention: impressions fromthe BIP and VA-HIT trials. Int J Cardiol 2002; 82: 199-207; discussion-8.
58. Backes JM, Gibson CA. Effect of lipid-lowering drug therapy onsmall-dense low-density lipoprotein. Ann Pharmacother 2005; 39:523-6.
59. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses inpatients with atherogenic dyslipidemia. Am J Cardiol 2001; 88:270-4.
60. Superko HR, Garrett BC, King SB, 3rd, Momary KM, Chronos NA., Wood PD. Effect of combination nicotinic acid and gemfibroziltreatment on intermediate density lipoprotein, and subclassesof low density lipoprotein and high density lipoprotein in patientswith combined hyperlipidemia. Am J Cardiol 2009; 103: 387-92.
61. Superko HR, Berneis KK, Williams PT, Rizzo M, Wood PD. Gemfibrozilreduces small low-density lipoprotein more in normolipemicsubjects classified as low-density lipoprotein pattern B comparedwith pattern A. Am J Cardiol 2005; 96: 1266-72.
62. Superko HR, Krauss RM. Differential effects of nicotinic acid insubjects with different LDL subclass patterns. Atherosclerosis 1992; 95: 69-76.
63. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, andtolerability of once-daily niacin for the treatment of dyslipidemiaassociated with type 2 diabetes: results of the assessment of diabetescontrol and evaluation of the efficacy of niaspan trial. Arch InternMed 2002; 162: 1568-76.
64. Nordoy A, Hansen JB, Brox J, Svensson B. Effects of atorvastatinand omega-3 fatty acids on LDL subfractions and postprandial hyperlipemiain patients with combined hyperlipemia. Nutr MetabCardiovasc Dis 2001; 11: 7-16.
65. Stalenhoef AF, de Graaf J, Wittekoek ME, Bredie SJ, Demacker PN, Kastelein JJ. The effect of concentrated n-3 fatty acids vs.gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneityand oxidizability in patients with hypertriglyceridemia.Atherosclerosis 2000; 153: 129-38.
66. Patti L, Maffettone A, Iovine C, et al. Long-term effects of fish oilon lipoprotein subfractions and low density lipoprotein size in noninsulin-dependent diabetic patients with hypertriglyceridemia.Atherosclerosis 1999; 146: 361-7.
67. Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HA. Metaanalysisof the effects of n-3 polyunsaturated fatty acids on lipoproteinsand other emerging lipid cardiovascular risk markers in patientswith type 2 diabetes. Diabetologia 2007; 50: 1593-602.
68. Gaw A, Packard CJ, Lindsay GM, et al. Effects of colestipol aloneand in combination with simvastatin on apolipoprotein B metabolism.Arterioscler Thromb Vasc Biol 1996; 16: 236-49.
69. Rosenson RS, Abby SL, Jones MR. Colesevelam HCl effects onatherogenic lipoprotein subclasses in subjects with type 2 diabetes.Atherosclerosis 2009; 204: 342-4.
70. Rosenson RS. Colesevelam HCl reduces LDL particle number andincreases LDL size in hypercholesterolemia. Atherosclerosis 2006;185: 327-30.
71. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Resultsof the glucose-lowering effect of WelChol study (GLOWS): a randomized,double-blind, placebo-controlled pilot study evaluatingthe effect of colesevelam hydrochloride on glycemic control in subjectswith type 2 diabetes. Clin Ther 2007; 29: 74-83.
72. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Colesevelamhydrochloride in clinical practice: a new approach in thetreatment of hypercholesterolaemia. Curr Med Res Opin 2008; 24:995-1009.
73. Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H. Effects of simvastatin andciprofibrate alone and in combination on lipid profile, plasma fibrinogenand low density lipoprotein particle structure and distributionin patients with familial combined hyperlipidaemia and coronaryartery disease. Coron Artery Dis 1996; 7: 843-50.
74. Farnier M, Perevozskaya I, Taggart WV, Kush D, Mitchel YB. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemicpatients on treatment with ezetimibe/simvastatin and fenofibrate. JLipid Res 2008; 49: 2641-7.
75. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat,sibutramine, and rimonabant. Lancet 2007; 369: 71-7.
76. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat onmetabolic parameters and other cardiovascular risk factors. DiabetesMetab 2005; 31: 15-22.
77. Tsimihodimos V, Miltiadous G, Daskalopoulou SS, MikhailidisDP, Elisaf MS. Fenofibrate: metabolic and pleiotropic effects. CurrVasc Pharmacol 2005; 3: 87-98.
78. Florentin M, Liberopoulos EN, Tellis CC, Derdemezis CS, Elisaf MS, Tselepis AD. Effects of rimonabant, as monotherapy and incombination with fenofibrate or ezetimibe, on plasma adipokinelevels: a pilot study. Angiology 2010; 61: 365-71.
79. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolicrisk factors in overweight patients with dyslipidemia. N EnglJ Med 2005; 353: 2121-34.
80. Despres JP, Ross R, Boka G, Almeras N, Lemieux I. Effect ofrimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia,intraabdominal adiposity, and liver fat: the ADAGIO-Lipidstrial. Arterioscler Thromb Vasc Biol 2009; 29: 416-23.
81. Florentin M, Liberopoulos EN, Filippatos TD, et al. Effect of rimonabant,micronised fenofibrate and their combination on cardiometabolicrisk factors in overweight/obese patients: a pilotstudy. Expert Opin Pharmacother 2008; 9: 2741-50.
82. Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP. VISFATIN/PBEF and Atherosclerosis-Related Diseases.Curr Vasc Pharmacol 2010; 8: 12-28.
83. Mannucci E, Dicembrini I, Rotella F, Rotella CM. Orlistat andsibutramine beyond weight loss. Nutr Metab Cardiovasc Dis 2008;18: 342-8.
84. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapyfor obesity and overweight: updated meta-analysis.BMJ 2007; 335: 1194-9.
85. Rizzo M, Berneis K. The clinical relevance of low-densitylipoproteinssize modulation by statins. Cardiovasc Drugs Ther 2006; 20: 205-17.
86. Chung M, Lichtenstein AH, Ip S, Lau J, Balk EM. Comparabilityof methods for LDL subfraction determination: A systematic review.Atherosclerosis 2009; 205: 342-8.